Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT

Clasificación en acciones #4051
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Precio por acción
$31.91
Última sincronización: 2026-10-21
Capitalización bursátil
$4.01B
Cambio (1 día)
-2.77%
Cambio (1 año)
61.08%
País
US
Comercio Arcutis Biotherapeutics, Inc. (ARQT)

Categoría

Healthcare
Historial del precio de la acción de Arcutis Biotherapeutics, Inc. (ARQT)
Precio más alto de cierre: $27.20 el 2026-10-01

Precio más bajo de cierre: $21.80 el 2020-01-01
Historial del precio de la acción de Arcutis Biotherapeutics, Inc. desde 2020 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -13.06%
2025 117.39%
2024 438.98%
2023 -84.13%
2022 -9.27%
2021 -38.74%
2020 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$527.18 23.62%
US
$251.29 835.90%
US
$137.73 -3.85%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH